Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells

Science Translational Medicine

Volumn 2, Issue 17, 2010, Pages

  Saito, Yoriko ^a   Kitamura, Hiroshi ^a   Hijikata, Atsushi ^a   Tomizawa Murasawa, Mariko ^a   Tanaka, Satoshi ^b   Takagi, Shinsuke ^a   Uchida, Naoyuki ^c   Suzuki, Nahoko ^a   Sone, Akiko ^a   Najima, Yuho ^a   Ozawa, Hidetoshi ^a   Wake, Atsushi ^c   Taniguchi, Shuichi ^c   Shultz, Leonard D ^d   Ohara, Osamu ^a   Ishikawa, Fumihiko ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

^b Nippon Becton Dickinson   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD32 ANTIGEN; CYTARABINE; HEMATOPOIETIC CELL KINASE; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTOME; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL CYCLE; CELL FUNCTION; CELL SURFACE; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA STEM CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SCREENING TEST; STEM CELL NICHE; TARGET CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CELL CYCLE; CELL LINEAGE; CELL SEPARATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; RECEPTORS, IGG; TRANSPLANTATION, HETEROLOGOUS;

EID: 77749294821     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000349     Document Type: Article

References (52)

1. M. J. Horner, L. A. G. Ries, M. Krapcho, N. Neyman, R. Aminou, N. Howlader, S. F. Altekruse, E. J. Feuer, L. Huang, A. Mariotto, B. A. Miller, D. R. Lewis, M. P. Eisner, D. G. Stinchcomb, B. K. Edwards, SEER Cancer Statistics Review, 1975-2006 (National Cancer Institute, Bethesda, 2009); http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission [accessed 2 July 2009].
2. D. A. Breems, W. L. Van Putten, P. C. Huijgens, G. J. Ossenkoppele, G. E. Verhoef, L. F. Verdonck, E. Vellenga, G. E. De Greef, E. Jacky, J. Van der Lelie, M. A. Boogaerts, B. Löwenberg, Prognostic index for adult patients with acute myeloid leukemia in first relapse. J. Clin. Oncol. 23, 1969-1978 (2005).
3. D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C. J. Harrison, K. Wheatley, A. K. Burnett, A. H. Goldstone; Medical Research Council Adult Leukemia Working Party, The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312-1320 (2001).
4. D. Grimwade, H.Walker, F.Oliver, K.Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, A. Goldstone, The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92, 2322-2333 (1998).
5. T. Lapidot, C. Sirard, J. Vormoor, B.Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M. A. Caligiuri, J. E. Dick, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
6. M. F. Clarke, J. E. Dick, P. B. Dirks, C. J. Eaves, C. H. Jamieson, D. L. Jones, J. Visvader, I. L. Weissman, G. M. Wahl, Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339-9344 (2006).
7. F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. Nakamura, T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. Ohshima, N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L. D. Shultz, Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25, 1315-1321 (2007).
8. F. Hong, R. Breitling, C. W. McEntee, B. S. Wittner, J. L. Nemhauser, J. Chory, RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22, 2825-2827 (2006).
9. R. Breitling, P. Armengaud, A. Amtmann, P. Herzyk, Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573, 83-92 (2004).
10. Bioconductor, http://www.bioconductor.org/.
11. J. C. Byrd, K. Mrózek, R. K. Dodge, A. J. Carroll, C. G. Edwards, D. C. Arthur, M. J. Pettenati, S. R. Patil, K. W. Rao, M. S. Watson, P. R. Koduru, J. O. Moore, R. M. Stone, R. J. Mayer, E. J. Feldman, F. R. Davey, C. A. Schiffer, R. A. Larson, C. D. Bloomfield; Cancer and Leukemia Group B (CALGB 8461), Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100, 4325-4336 (2002).
12. E. Estey, H. Döhner, Acute myeloid leukaemia. Lancet 368, 1894-1907 (2006).
13. C.Gardin, P.Turlure, T. Fagot, X. Thomas, C.Terre, N. Contentin, E. Raffoux, S. deBotton, C.Pautas, O. Reman, J. H. Bourhis, P. Fenaux, S. Castaigne, M. Michallet, C. Preudhomme, T. de Revel, D. Bordessoule, H. Dombret, P os tremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109, 5129-5135 (2007).
14. M. L. Slovak, K. J. Kopecky, P. A. Cassileth, D. H. Harrington, K. S. Theil, A. Mohamed, E. Paietta, C. L. Willman, D. R. Head, J. M. Rowe, S. J. Forman, F. R. Appelbaum, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96, 4075-4083 (2000).
15. P. J. Valk, R. G. Verhaak, M. A. Beijen, C. A. Erpelinck, S. Barjesteh van Waalwijk van Doorn- Khosrovani, J. M. Boer, H. B. Beverloo, M. J. Moorhouse, P. J. van der Spek, B. Löwenberg, R. Delwel, Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004).
16. K. H. Metzeler, M. Hummel, C. D. Bloomfield, K. Spiekermann, J. Braess, M. C. Sauerland, A. Heinecke, M. Radmacher, G. Marcucci, S. P. Whitman, K. Maharry, P. Paschka, R. A. Larson, W. E. Berdel, T. Büchner, B. Wörmann, U. Mansmann, W. Hiddemann, S. K. Bohlander, C. Buske; Cancer and Leukemia Group B; German AML Cooperative Group, An 86-probe-set gene expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112, 4193-4201 (2008).
17. G. Marcucci, M. D. Radmacher, K. Maharry, K. Mrózek, A. S. Ruppert, P. Paschka, T. Vukosavljevic, S. P. Whitman, C. D. Baldus, C. Langer, C. G. Liu, A. J. Carroll, B. L. Powell, R. Garzon, C. M. Croce, J. E. Kolitz, M. A. Caligiuri, R. A. Larson, C. D. Bloomfield, MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1919-1928 (2008).
18. C. Langer, M. D. Radmacher, A. S. Ruppert, S. P. Whitman, P. Paschka, K. Mrózek, C. D. Baldus, T. Vukosavljevic, C. G. Liu, M. E. Ross, B. L. Powell, A. de la Chapelle, J. E. Kolitz, R. A. Larson, G. Marcucci, C. D. Bloomfield; Cancer and Leukemia Group B (CALGB), High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct geneexpression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 111, 5371-5379 (2008).
19. R. Liu, X. Wang, G. Y. Chen, P. Dalerba, A. Gurney, T. Hoey, G. Sherlock, J. Lewicki, K. Shedden, M. F. Clarke, The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226 (2007).
20. R. Majeti, M. W. Becker, Q. Tian, T. L. Lee, X. Yan, R. Liu, J. H. Chiang, L. Hood, M. F. Clarke, I. L. Weissman, Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. U.S.A. 106, 3396-3401 (2009).
21. C. Rosenfeld, M. A. Cheever, A. Gaiger, WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: Therapeutic potential of WT1 targeted therapies. Leukemia 17, 1301-1312 (2003).
22. H. B. Ommen, C. G. Nyvold, K. Braendstrup, B. L. Andersen, I. B. Ommen, H. Hasle, P. Hokland, M. Ostergaard, Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: Development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br. J.Haematol. 141, 782-791 (2008).
23. K. Inoue, H. Sugiyama, H. Ogawa, M. Nakagawa, T. Yamagami, H. Miwa, K. Kita, A. Hiraoka, T. Masaoka, K. Nasu, T. Kyo, H. Dohy, H. Nakauchi, T. Ishidate, T. Akiyama, T. Kishimoto, WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84, 3071-3079 (1994).
24. L. Bergmann, C. Miething, U. Maurer, J. Brieger, T. Karakas, E. Weidmann, D. Hoelzer, High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90, 1217-1225 (1997).
25. U. Keilholz, A. Letsch, A. Busse, A. M. Asemissen, S. Bauer, I. W. Blau, W. K. Hofmann, L. Uharek, E. Thiel, C. Scheibenbogen, A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113, 6541-6548 (2009).
26. T. Kitawaki, N. Kadowaki, T. Kondo, T. Ishikawa, T. Ichinohe, S. Teramukai, M. Fukushima, Y. Kasai, T. Maekawa, T. Uchiyama, Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyholelimpet- hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am. J. Hematol. 83, 315-317 (2008).
27. K. Rezvani, A. S. Yong, S. Mielke, B. N. Savani, L. Musse, J. Superata, B. Jafarpour, C. Boss, A. J. Barrett, Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-242 (2008).
28. N. Quintrell, R. Lebo, H. Varmus, J. M. Bishop, M. J. Pettenati, M. M. Le Beau, M. O. Diaz, J. D. Rowley, Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells. Mol. Cell. Biol. 7, 2267-2275 (1987).
29. S. F. Ziegler, J. D. Marth, D. B. Lewis, R. M. Perlmutter, Novel protein-tyrosine kinase gene (hck) preferentially expressed in cells of hematopoietic origin. Mol. Cell. Biol. 7, 2276-2285 (1987).
30. O. Mitina, M. Warmuth, G. Krause, M. Hallek, A. Obermeier, Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Ann. Hematol. 86, 777-785 (2007).
31. M. Terwijn, N. Feller, A. van Rhenen, A. Kelder, G. Westra, S. Zweegman, G. Ossenkoppele, G. J. Schuurhuis, Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur. J. Cancer 45, 1692-1699 (2009).
32. T. Takai, M. Ono, M. Hikida, H. Ohmori, J. V. Ravetch, Augmented humoral and anaphylactic responses in FcgRII-deficient mice. Nature 379, 346-349 (1996).
33. S. Bolland, J. V. Ravetch, Spontaneous autoimmune disease in FcgRIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277-285 (2000).
34. R. Sharma, H. Bagavant, W. N. Jarjour, S. S. Sung, S. T. Ju, The role of Fas in the immune system biology of IL-2Ra knockout mice: Interplay among regulatory T cells, inflammation, hemopoiesis, and apoptosis. J. Immunol. 175, 1965-1973 (2005).
35. D. M. Willerford, J. Chen, J. A. Ferry, L. Davidson, A. Ma, F. W. Alt, Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
36. J. E. Salmon, S. Millard, L. A. Schachter, F. C. Arnett, E. M. Ginzler, M. F. Gourley, R. Ramsey-Goldman, M. G. Peterson, R. P. Kimberly, FcgRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J. Clin. Invest. 97, 1348-1354 (1996).
37. K. L. Moser, B. R. Neas, J. E. Salmon, H. Yu, C. Gray-McGuire, N. Asundi, G. R. Bruner, J. Fox, J. Kelly, S. Henshall, D. Bacino, M. Dietz, R. Hogue, G. Koelsch, L. Nightingale, T. Shaver, N. I. Abdou, D. A. Albert, C. Carson, M. Petri, E. L. Treadwell, J. A. James, J. B. Harley, Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome 1q in African-American pedigrees. Proc. Natl. Acad. Sci. U.S.A. 95, 14869-14874 (1998).
38. V. De Rose, C. Arduino, N. Cappello, R. Piana, P. Salmin, M. Bardessono, M. Goia, R. Padoan, E. Bignamini, D. Costantini, G. Pizzamiglio, V. Bennato, C. Colombo, A. Giunta, A. Piazza, Fcg receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis. Eur. J. Hum. Genet. 13, 96-101 (2005).
39. N. Sharfe, H. K. Dadi, M. Shahar, C. M. Roifman, Human immune disorder arising from mutation of the a chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. U.S.A. 94, 3168-3171 (1997). (Pubitemid 27157282)
40. O. J. Brand, C. E. Lowe, J. M. Heward, J. A. Franklyn, J. D. Cooper, J. A. Todd, S. C. Gough, Association of the interleukin-2 receptor alpha (IL-2Ra)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. (Oxf.) 66, 508-512 (2007).
41. E. J. Carr, M. R. Clatworthy, C. E. Lowe, J. A. Todd, A. Wong, T. J. Vyse, L. Kamesh, R. A. Watts, P. A. Lyons, K. G. Smith, Contrasting genetic association of IL2RA with SLE and ANC Aassociated vasculitis. BMC Med. Genet. 10, 22 (2009).
42. International Multiple Sclerosis Genetics Consortium; D. A. Hafler, A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. de Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, M. A. Pericak-Vance, S. G. Gregory, J. D. Rioux, J. L. McCauley, J. L. Haines, L. F. Barcellos, B. Cree, J. R. Oksenberg, S. L. Hauser, Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851-862 (2007).
43. C. E. Lowe, J. D. Cooper, T. Brusko, N. M. Walker, D. J. Smyth, R. Bailey, K. Bourget, V. Plagnol, S. Field, M. Atkinson, D. G. Clayton, L. S. Wicker, J. A. Todd, Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39, 1074-1082 (2007).
44. A. Vella, J. D. Cooper, C. E. Lowe, N. Walker, S. Nutland, B. Widmer, R. Jones, S. M. Ring, W. McArdle, M. E. Pembrey, D. P. Strachan, D. B. Dunger, R. C. Twells, D. G. Clayton, J. A. Todd, Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76, 773-779 (2005).
45. F. Vincenti, R. Kirkman, S. Light, G. Bumgardner, M. Pescovitz, P. Halloran, J. Neylan, A. Wilkinson, H. Ekberg, R. Gaston, L. Backman, J. Burdick, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.N. Engl. J. Med. 338, 161-165 (1998).
46. B. Nashan, S. Light, I. R. Hardie, A. Lin, J. R. Johnson, Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67, 110-115 (1999).
47. L. Jin, E. M. Lee, H. S. Ramshaw, S. J. Busfield, A. G. Peoppl, L. Wilkinson, M. A. Guthridge, D. Thomas, E. F. Barry, A. Boyd, D. P. Gearing, G. Vairo, A. F. Lopez, J. E. Dick, R. B. Lock, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor a chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5, 31-42 (2009).
48. L. D. Shultz, B. L. Lyons, L. M. Burzenski, B. Gott, X. Chen, S. Chaleff, M. Kotb, S. D. Gillies, M. King, J. Mangada, D. L. Greiner, R. Handgretinger, Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rgnull mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-6489 (2005).
49. F. Ishikawa, M. Yasukawa, B. Lyons, S. Yoshida, T. Miyamoto, G. Yoshimoto, T. Watanabe, K. Akashi, L. D. Shultz, M. Harada, Development of functional human blood and immune systems in NOD/SCID/IL2 receptor g chainnull mice. Blood 106, 1565-1573 (2005).
50. Ingenuity Systems, http://www.ingenuity.com.
51. Gene Ontology Annotation, http://www.ebi.ac.up/GOA/.
52. A. Giulietti, L. Overbergh, D. Valckx, B. Decallonne, R. Bouillon, C. Mathieu, An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression. Methods 25, 386-401 (2001).